IP Waiver Might Kick-Start China's Novel COVID-19 Vaccine Effort
Executive Summary
As the US responds to calls to waive intellectual property rights related to COVID-19 vaccines, China is already moving ahead with some of its own mRNA candidates.
You may also be interested in...
Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?
IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.
Speed Bumps Ahead For IP Waiver, But Will It Nudge Voluntary Licensing?
IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.
Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?
IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.